- Home
- VEL vs EOLS Comparison
VEL vs EOLS Comparison
Compare VEL & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- EOLS
- Stock Information
- Founded
- VEL 2004
- EOLS 2012
- Country
- VEL United States
- EOLS United States
- Employees
- VEL N/A
- EOLS N/A
- Industry
- VEL Finance: Consumer Services
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- EOLS Health Care
- Exchange
- VEL Nasdaq
- EOLS Nasdaq
- Market Cap
- VEL 680.6M
- EOLS 589.3M
- IPO Year
- VEL 2020
- EOLS 2018
- Fundamental
- Price
- VEL $17.30
- EOLS $9.28
- Analyst Decision
- VEL Buy
- EOLS Strong Buy
- Analyst Count
- VEL 5
- EOLS 5
- Target Price
- VEL $21.20
- EOLS $23.75
- AVG Volume (30 Days)
- VEL 82.5K
- EOLS 867.8K
- Earning Date
- VEL 08-07-2025
- EOLS 08-05-2025
- Dividend Yield
- VEL N/A
- EOLS N/A
- EPS Growth
- VEL 14.80
- EOLS N/A
- EPS
- VEL 1.94
- EOLS N/A
- Revenue
- VEL $177,987,000.00
- EOLS $275,463,000.00
- Revenue This Year
- VEL N/A
- EOLS $33.42
- Revenue Next Year
- VEL $32.82
- EOLS $33.18
- P/E Ratio
- VEL $8.91
- EOLS N/A
- Revenue Growth
- VEL 39.36
- EOLS 25.38
- 52 Week Low
- VEL $16.12
- EOLS $8.67
- 52 Week High
- VEL $20.98
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- VEL 37.88
- EOLS 45.32
- Support Level
- VEL $17.40
- EOLS $9.00
- Resistance Level
- VEL $17.99
- EOLS $10.20
- Average True Range (ATR)
- VEL 0.35
- EOLS 0.40
- MACD
- VEL -0.10
- EOLS 0.03
- Stochastic Oscillator
- VEL 3.34
- EOLS 23.33
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.